Biological risk now spans a continuum from ordinary evolution to deliberate engineering. Natural pathogens continue to mutate, recombine, cross species, and propagate in ways that strain traditional forecasting. Known organisms can be deliberately modified to increase transmissibility, resistance, environmental stability, host range, or immune escape. Synthetic biology and AI-enabled sequence design can also create constructs that fall outside conventional pathogen lists or resemble biological “dark matter” in complex samples.

The supplied threat-scenario materials organize this environment into three broad classes. New biology includes AI-enabled synthetic systems whose sequences or functions may not be represented in existing reference databases. Modified biology involves engineered enhancements to known organisms, potentially degrading diagnostics or countermeasures. Existing biology includes deliberate use of natural pathogens against people, livestock, crops, water systems, supply chains, or public infrastructure. Each class creates different signatures, but all produce early fragments of evidence across multiple systems.

Current surveillance architectures are generally organized around local missions.

• Clinical laboratories identify causes of illness.
• Public-health systems aggregate reportable conditions.
• Environmental programs monitor wastewater or water quality.
• Agricultural agencies monitor crops and livestock.
• Defense laboratories support force health and specific threat missions.

These systems generate valuable information, but their data standards, thresholds, analytic methods, and authorities differ. The resulting gaps are structural rather than scientific.

Four recurring barriers define the problem.

• Governance is fragmented and data exchange is restricted.
• Data are packaged in heterogeneous syntactic and semantic standards.
• Reference databases vary in quality and provenance.
• Analytic workflows differ across organizations and are difficult to validate consistently.

Once a trusted reference layer exists, the next challenge is computational. A modern biological sample can contain millions or billions of sequencing reads from multiple organisms, hosts, contaminants, and background species. The important signal may be a low-abundance pathogen, a divergent strain, a structural rearrangement, a small subpopulation, an unmapped fragment, or an expressed protein that changes the risk interpretation. No single alignment or classifier is sufficient.

The High-performance Integrated Virtual Environment, or HIVE, was originally developed as a secure distributed storage and computing environment for next-generation sequencing. Official FDA materials describe it as a multicomponent infrastructure providing authorized users with secure web access to deposit, retrieve, annotate, compute on, and visualize large NGS datasets. BIONET exploits the current HIVE/H2O platform as a production-grade environment spanning genomics, multi-omics, imaging, clinical metadata, massively parallel analytics, provenance, security controls, APIs, and role-based visualization.

The regulatory context is a major differentiator. The FDA states that HIVE has maintained an FDA Authorization to Operate since 2012 and characterizes it as the ATO-ed platform at FDA fit for maintaining and computing on large-scale multi-omics datasets. They further report that FDA has used HIVE for research and regulatory review since 2011, with more than 27 petabytes of genomic information across 20 deployed U.S. instances.

FDA describes HIVE as supporting the genomic core and regulatory work across cell and gene therapies, vaccines, diagnostics, microbial therapeutics, oncology, hematology, CRISPR-based products, T-cell therapies, AAV and protein-delivery systems, pathogen detection, and vaccine safety. That breadth matters to BIONET because the platform is not a narrow pathogen classifier. It is a regulated computational ecosystem designed to maintain very large data assets, execute versioned pipelines, preserve provenance, and expose results through scientific interfaces.

BIONET’s HIVE detection stack is layered to answer the following questions.

• Which organisms are present? Identity.
• How different is this organism from what we knew?
• How does the pathogen impact us? Function.
• Has this pathogen been altered?
• Is the pathogen diversifying itself to avoid detection?
• What is the dark matter of completely unknown species?
• Are the pathogens active?
• Are our detection signals part of normal evolution or adversarial design?

The final product is not a raw bioinformatics report. The BIONET portal concept separates technician triage, sample inventory, analyst diversity views, administrative controls, expert evidence review, and command reporting.

The signals on sample analysis can have different status: gray for processing, green for expected baseline, orange for elevated but explainable activity, red for unexpected pathogen or functional/propagation signal requiring attention, and blue for sample or data-quality failure.

This structure shortens the path from computation to action while preserving access to the underlying evidence.

Problem: The global biological environment cannot be monitored by a static pathogen list, a single sequencing algorithm, or one centralized repository. BIONET integrates the full chain while accepting that the most important data will remain distributed and independently governed.

BIONET is therefore best understood not as another surveillance database, but as a biological intelligence operating system: a secure, federated, regulatory-grounded capability that integrates existing sensors and institutions into a common Indications and Warning (I&W) architecture for naturally evolving pathogens and adversarial biological constructs.

BIONET integrates existing sensing, laboratory, and information systems; it does not require every participant to become the same kind of organization or abandon its current mission.

The U.S. operating concept is intentionally heterogeneous. A wastewater site may contribute routine population-level pathogen signals. A hospital may contribute clinical sequencing and selected outcomes under local privacy rules. A port may contribute environmental or cargo-related observations. Agricultural laboratories may monitor livestock and crop pathogens. State and CDC laboratories may contribute confirmatory public-health data. Defense laboratories may contribute force-health, installation, or mission-specific observations. Overseas partners may contribute local analysis without exporting underlying data.

The value is not simply the number of nodes. It is the ability to analyze comparable observables across domains and time. A pathogen appearing in wastewater, a clinical laboratory, a transport hub, and an agricultural environment may mean something very different from a single isolated detection. BIONET allows common analytics and reference versions to test whether those signals represent expected background, correlated propagation, cross-species movement, a supply-chain event, or an anomalous deployment pattern.

The network also supports different connectivity modes. Connected nodes can receive updated references, applications, and models through certified repositories and participate in continuous surveillance. Intermittently connected or contested nodes can receive signed HIVE-in-a-Box updates through controlled offline media, execute locally, and synchronize approved outputs later. The analytic definition remains consistent even when network conditions differ.

Internationally, federation is not merely a technical convenience. It is a diplomatic and sovereignty mechanism. Partners may be willing to run a transparent, validated analytic package inside their own infrastructure even when they are unwilling or legally unable to export genomic or clinical data. A common reference and analytic standard can therefore create shared warning without requiring shared custody of every record.

WHAT BIONET IS NOTBIONET is not a replacement for CDC, FDA, state, clinical, agricultural, defense, or international systems. It is the reference, analytic, federation, and signaling layer that allows those systems to contribute to a common biological warning picture.

The BIONET workflow converts a locally collected sample into a governed, explainable signal and then into role-appropriate decision support.

A minimum data package is essential for consistent operations. At a minimum, BIONET should define raw or processed sequence location, sample and assay quality attributes, collection time and location, specimen or environmental source, instrument and protocol version, relevant host or site context, ARGOS and HIVE release identifiers, transformation history, thresholds, and escalation logic. Sites may contribute more context, but the minimum package should be stable enough to support comparison across the network.

Verification and validation should be scenario-driven. Known-pathogen tests establish sensitivity, specificity, and reproducibility. Divergent-strain and recombinant challenges test structural interpretation. Synthetic controls test engineered-element detection without requiring operational threat agents. Longitudinal simulations test time-to-warning, false-positive burden, and model behavior. Multi-site exercises test governance, network operations, and command handoff rather than only algorithm accuracy.

The workflow must preserve local action. A site should not wait for a national command center to correct an obvious quality failure or respond to a locally significant pathogen. BIONET adds shared awareness and common escalation; it does not remove the authority of local operators. This dual-level design is necessary for both resilience and adoption.